We’ve rebranded some of our products, learn more ›
Webinar Series: October 6-27, 2021
Recent developments in the study of spatial biomarkers continue to demonstrate the predictive power of this new class of biomarker assays. Watch this four-part webinar series to learn how researchers are pioneering new strategies representing significant milestones that advance spatial biology into the realm of patient phenotyping and improving immunotherapy outcomes in the future. The use of multiplex immunofluorescence (mIF) technologies such as Akoya’s PhenoImager™ platform (formerly Phenoptics™), has enabled researchers to continue to reveal the power of spatial phenotypic signatures in advancing the path for more effective drug development from clinical trial design through standardization. Hear from our expert panel on recent developments that establishes the vital role of spatial biomarkers in setting the future directions in achieving precision immuno-oncology.
The I-SPY 2 (investigation of serial studies to predict your therapeutic response with imaging and molecular analysis) is an adaptive clinical trial platform that supports the rapid, focused clinical development of paired oncologic therapies and biomarkers. The goal is to identify improved treatment regimens based on the molecular characteristics of individual patients’ disease.
In this webinar, Dr. Laura Esserman and Dr. Michael Campbell discuss the I-SPY 2 trial of neoadjuvant treatment for locally advanced breast cancer. The trial involved the use of mIF-based biomarker panels, developed with the PhenoImager platform, to map the heterogeneity of the tumor microenvironment.
Drs. Esserman and Campbell have standardized biomarker discovery and development efforts on the PhenoImager platform to measure as many as six markers at a time on a single pathology slide using mIF. They discuss how I-SPY 2 has the potential to significantly accelerate the time to get effective treatments to the patients who will benefit, while also reducing the cost of drug development.
In this talk, attendees will:
In this webinar, Dr. Bernard Fox and Elizabeth Engle discuss the results of the Multi-Institutional TSA-amplified Multiplexed Immunofluorescence Reproducibility Evaluation (MITRE Study), published in the Journal for ImmunoTherapy of Cancer (JITC) in July 2021. The MITRE study is the first multi-institutional study involving mIF designed to develop and validate a spatial biology workflow that is transferable among sites and delivers site-independent and reliable quantitative data for immunotherapy research. The MITRE results are an important step toward standardizing an automated mIF-based spatial biology workflow that provides the level of performance needed to support clinical trials and that can be applied to clinical testing in the future.
In this webinar, Dr. Kurt Schalper discusses the immune composition and therapeutic implications in human non-small cell lung cancer (NSCLC), focusing on dominant immune evasion pathways and T-cell dysfunction. He presents results from studies using genomic and spatially resolved analysis of different cells types and targets/pathways that have shed light on the complexity of the tumor/immune cell interactions and their role in sensitivity and resistance to immunostimulatory anti-cancer therapies. He also discusses the potential application of these concepts for future biomarker development and novel treatment strategies.
This multi-stakeholder panel discussion brings together a diverse set of experts who will highlight innovative solutions that demonstrate the integral role of spatial biomarkers in immuno-oncology. Learn about their advancements from biomarker discovery to translational research, and how they are shaping the future direction of the spatial biology field.
Sign up to receive our eNewsletter, new product updates, events, and more!